Cantargia has reported data from two clinical trials including nadunolimab combination therapy in 55 cancer patients. Both trials show strong antitumor effects as well as very encouraging median survival times
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
NLS News
The company has recently raised SEK 10 million in directed issue for a novel obesity-related study. The aim is to study drug tolerance and the effects of the company’s molecule
Advertisement
IRLAB Therapeutics has announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the
In a recent study published in Nature, Swedish researchers demonstrate the role of sex hormones in regulating the immune system. This newfound knowledge explains differences between men and women and
The European Commission has granted Orphan Medicinal Product Designation (OMPD) to the company’s lead drug candidate CS1 in the rare disease Pulmonary Arterial Hypertension (PAH). “This designation offers significant advantages,
The Theranostics Trial Center (TTC) at Karolinska University Hospital has been awarded financing from Vinnova to run a new project in precision medicine. By combining image-guided diagnostics and therapy with
Business Region Göteborg and AstraZeneca have entered a strategic collaboration with the aim to further strengthen the entire life science sector and create jobs and growth in the region. “In
Rokote Laboratories Finland has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate expressing a modified spike protein of severe acute respiratory coronavirus
Advertisement
Swedish pharmaceutical exports continue to develop positively according to new figures from Statistics Sweden (SCB). Sweden’s total exports increased by 4 percent in value and two percent in volume during
An agreement has been signed between Oslo City Council and Oslo Science Hub to sell the lots necessary for the planned building that will transform the Oslo Montebello area into
AstraZeneca is making an additional investment of USD 135 million in its facility for biologics in Södertälje. “We are happy about this investment in Södertälje, which demonstrates AstraZeneca’s commitment to
In a new publication in “Vaccines” from Department of Immunology and Microbiology, Centre for translational Medicine & Parasitology at Copenhagen University, Attana’s technology has been applied to determine the interaction
Getinge has announced an agreement to acquire 100% of Paragonix Technologies for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million. The acquisition
NADMED has closed a series A round to fund its entry into the U.S. and other international markets with its nicotinamide adenine dinucleotide (NAD) measurement technology that may help clinicians
Read the latest issue of our magazine!
No 03 2024 // This 100 page-issue includes a special report on the current financial landscape. We take a closer look on different challenges, advisors and legal experts share their advice and not least, companies share their experience, including having to downsize and bankruptcy. Our profile is professor Anna Wedell. She has focused her career on inherited metabolic diseases and is Director of the new Precision Medicine Center Karolinska. Another theme is Nordic strengths and we highlight success stories from different Nordic corners, everything from Europe’s first pluripotent stem-cell-based product to treat Parkinson’s to wound healing using fish skin. Our hot topic is the very important challenge to attract and retain talent from abroad, and three successful women in life sciences share their advice and insight. This, and much more!
Drug and Device Development
After a positive initial safety evaluation, the pioneering STEM-PD (stem cell-based transplant for Parkinson’s disease) clinical trial has advanced to higher dose testing. STEM-PD is a first-in-human clinical trial testing
Cantargia has reported data from two clinical trials including nadunolimab combination therapy in 55 cancer patients. Both trials show strong antitumor effects as well as very encouraging median survival times
“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there
Predicting 2024
Nordic Life Science asked Lene Gerlach, Partner, Eir Ventures, about her predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you predict will
Nordic Life Science asked Casper Breum, Managing Partner, Sound Bioventures, about his predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you predict
Nordic Life Science asked Ingrid Teigland Akay, Managing Partner, Hadean Ventures, about her predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you
Nordic Life Science asked Dan Akschuti, Equity Partner/Biotech Analyst, Pareto Securities, about his predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you
Nordic Life Science asked Pekka Simula, Partner, Innovestor Life Science, about his predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you predict
Upcoming events
For the past decade, Nordic Life Science Days (NLSDays) has been building business partnerships, highlighting innovations and showcasing all that the Nordic countries have to offer in the life science
Medical Devices Regulation Update: Exploring the Thriving Regulatory Landscape This year’s MedDev Day will focus on the attractiveness of the European regulatory landscape for medical devices, improvements made and future
Experience BIO-Europe and connect with delegates spanning the global life science ecosystem to propel dealmaking and innovation. Join over 5,500 attendees, representing more than 2,800 companies and over 60 countries.
Harmonizing Perspectives to Support Implementation of Common Objectives in Pharmacovigilance: Insights from the Nordic Region It is our pleasure to announce that the well-known Nordic Pharmacovigilance Day conference is taking
Careers
Promotions and hefty raises do not create leaders. While some people always want to sit in the driver’s seat, leadership – effective leadership – is a learned skill. Too often
Jeanette Edblad is the new Director of the Office for Life Sciences at the Government Offices in Sweden. NLS asked her about her new role and about Swedish life sciences.
The board of WntResearch has appointed Per Norlén as the company’s new CEO. Per Norlén has solid experience from the life science industry in general and the development of cancer
Careers
Jennie Ekbeck, CEO at Umeå Biotech Incubator, has been appointed Innovations Angel of 2015. With her drive and problem-solving mindset she wants to make exciting research into business ideas and
JOB ALERTS
Profile
When considering the significant industries in Norway, several obvious ones spring to mind: oil and gas, hydropower, property, and fishing. Life sciences would feature on very few lists, but that
In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive
The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years
The latest research news from the Nordic region
Science articles
An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular
The 2023 Ig Nobel Prizes celebrates for example backward reading and counting nostril hairs. The 2023 Ig Nobel Prizes were awarded at the 33rd First Annual Ig Nobel Prize ceremony,
Researchers at Karolinska Institutet have developed a molecular method able to detect whether or not bacteria respond to antibiotics within minutes. The findings are presented in the journal Nature Microbiology
Professor Jens Juul Holst has made discoveries that have strongly influenced how people with obesity or type 2 diabetes are treated today. Throughout a long career, this internationally recognized researcher
Professor Åslaug Helland is the recipient of the King Olav Vs Cancer Research Award 2023. “This is a great honor, and I am very happy about this recognition of the
In January 2023, the European Association for the Study of Obesity (EASO) and the Novo Nordisk Foundation (NNF) announced that they were establishing a new prize for an agenda-setting researcher
Nordic Life Science
The latest clinical trials
Cantargia has reported data from two clinical trials including nadunolimab combination therapy in 55 cancer patients. Both trials show strong antitumor effects as well as very encouraging median survival times
“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there
Verrica Pharmaceuticals reports results from its study investigating Lytix’s lead drug candidate LTX-315 in patients with basal cell carcinoma (BCC). In short, the result showed that 86 percent overall reduction
Affibody’s partner ACELYRIN has announced that the Phase 3 trial of the Affibody molecule izokibep in patients with hidradenitis suppurativa (HS) achieved its primary endpoint of HiSCR75 at 12 weeks, as
TikoMed has announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients
The topline data readout from the Phase II FOCUS trial demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival
Diamyd Medical has announced a successful interim analysis (non-futility test) for its ongoing precision medicine Phase 3 DIAGNODE-3 trial. The interim analysis, reviewed by an independent Data Safety Monitoring Board
Medivir has presented new data from its ongoing phase Ib/IIa study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced hepatocellular carcinoma (HCC) at the European Society of Medical Oncology, Gastrointestinal
Alligator Bioscience has announced positive 18-month follow-up data from the OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study